Google graduates its life sciences division; How will AbbVie use its FDA review voucher?;

@FierceBiotech: Baxalta bets on 'external innovation' to meet its $8.5B goal and ward off Shire. Article | Follow @FierceBiotech

@JohnCFierce: In a first for diabetes, Lilly and Boehringer's Jardiance prevents heart attacks, strokes in trial. FiercePharma story | Follow @JohnCFierce

@DamianFierce: Turing has a new Form D reflecting that $90M claim but now including warrants and a loan. SEC form | Follow @DamianFierce

> Google ($GOOG), as part of its Alphabet evolution, is turning its life sciences segment into a standalone division, bringing it out of the Google X umbrella under CEO Andrew Conrad. More

> What's AbbVie ($ABBV) going to do with the $350 million FDA shortcut it bought this week? EP Vantage considers whether the company should accelerate filgotinib, a next-generation rheumatoid arthritis treatment. Item

> Former President Jimmy Carter, diagnosed with melanoma that has spread to the brain, is receiving Merck's ($MRK) immunotherapy Keytruda. News

Medical Device News

@FierceMedDev: IYCMI yesterday: Startup nabs $5.3M to back 2015 launch for connected fertility thermometer, app. Article | Follow @FierceMedDev

@VarunSaxena2: Cannabics Pharma's extended-release medical marijuana capsules available in Colorado. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Lilly faces patent-infringement fight over 'Take-n-Slide' drug adherence tool. More from FiercePharma | Follow @EmilyWFierce

> Gauss raises $3.3M for real-time surgical blood loss monitoring system, iPad app. More

> Patient monitoring company expanding in Milwaukee, adding 150 jobs. Article

Pharma News

@FiercePharma: Beef producers lash out at USDA's choice of Humane Society vet for advisory panel. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: Mylan recalls more of the cancer meds made at Indian plants hit with FDA warning letter. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Purdue hones abuse-deterrent edge with painkiller safety campaign. FiercePharmaMarketing story | Follow @CarlyHFierce

> Nervous drugmakers await decision on Bass' Ampyra patent challenge. More

> Majority across political spectrum in U.S. favor government steps to cut drug prices. Article